藥品經(jīng)營使用環(huán)節(jié)減免違法責任處罰適用情形
摘 要 通過陳述現(xiàn)行法律法規(guī)中無過錯責任界定的法理依據(jù)、分析藥品經(jīng)營、使用環(huán)節(jié)中減免責條款使用現(xiàn)狀，明確藥品經(jīng)營企業(yè)、使用單位的責任范圍，同時明確梳理出其可以依法予以免責或者減輕處罰的具體情形，探索新《中華人民共和國藥品管理法》施行中具有可操作性的細則，為藥品事中事后監(jiān)管積極探索可行性方案。
關(guān)鍵詞 無過錯責任 藥品經(jīng)營使用環(huán)節(jié) 減免責條款 事中事后監(jiān)管
中圖分類號：R951 文獻標志碼：C 文章編號：1006-1533（2022）09-0047-03
引用本文 譚云. 藥品經(jīng)營使用環(huán)節(jié)減免違法責任處罰適用情形[J]. 上海醫(yī)藥， 2022， 43（9）： 47-49； 57.
Circumstances of application of the reduction or exemption of penalties for illegal liability in the process of drug distribution and usage
TAN Yun
（Shanghai Pharmaceutical Co.， Ltd.， Shanghai 200032， China）
ABSTRACT By stating the legal basis for the definition of the no-fault liability in current laws and regulations， analyzing the current situation of the use of the exemption clause in the process of drug distribution and usage， the scope of responsibility of drug trading enterprises and user units is clarified. According to the law， the specific circumstances in which they can be exempted from liability or mitigated punishment are sorted out. Moreover， the operable rules in the implementation of the new Drug Administration Law are explored to figure out a feasible scheme for the supervision of drugs during and after the event.
KEY WORDS no-fault liability； the process of drug distribution and usage； reducing and immunity from legal liability； supervision of drugs during and after the event
新版《中華人民共和國藥品管理法》[1]（以下簡稱《藥品管理法》）已于2019年12月1日起施行，對假劣藥條款做了大幅修訂。（剩余5626字）